- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03737786
SEACOAST 1- SEdAtion With COllAteral Support in Endovascular Therapy for Acute Ischemic Stroke (SEACOAST)
Title : SEACOAST 1 SEdAtion With COllAteral Support in Endovascular Therapy for Acute Ischemic Stroke 1: a Randomized Controlled Phase 2B Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study design:
SEACOAST 1 is a prospective, randomized, blinded endpoint trial comparing collateral vigor and clinical outcomes, focusing on two distinct sedation strategies:
- General anesthesia with mild hypercarbia (GAH) during the sedation up until full revascularization versus
- General anesthesia with normocarbia (GAN) during the sedation up until full revascularization
Neuroanesthesia protocol, focused on maintenance of baseline BP, avoidance of hypotension during induction, and targeted partial pressure of carbon monoxide (PCO2) levels (normocarbia or mild hypercarbia):
- Anesthesia must not delay target initiation of procedure (groin puncture) of 90 min from ED arrival
- Standard American Society of Anesthesiologists (ASA) monitoring: 5 lead ECG, end-tidal CO2 (ETCO2), Pulse oximeter, BP monitor, Body temperature per esophageal probe, ET gas analyser
- Neuromuscular block (NMB) monitor for depth of neuromuscular blockade
- Arterial line placement is encouraged if it can be inserted within 5 min. Otherwise noninvasive BP per cuff. If arterial line has not been placed prior to induction monitor noninvasive blood pressure (NIBP) every 1 min per cuff until arterial line becomes available.
BP goals - keep at baseline with goal of no more than 10% drop (last recorded BP prior to induction) and cannot exceed 185/105 if patients received intravenous tissue plasminogen activator (IV TPA).
*BP can be lowered to desired goal only after revascularization as deemed necessary by the neurointerventional physician
- Induction with propofol or etomidate and rocuronium 1.2 mg/kg or succinylcholine
- Short acting vasoactive drugs (Phenylephrine, Ephedrine, Esmolol, Clevidipine) should be readily available to maintain BP in the predefined range throughout procedure. Phenylephrine drip recommended to maintain BP
- Anesthesia maintenance with volatile anesthetic and fentanyl; doses to be titrated to BP per anesthesiologist
- Qualitative end-tidal CO2 (ETCO2) measurement
- Immediately upon groin puncture interventionalist will provide blood gas sample to test arterial C02
A. Normocarbia arm:
Controlled ventilation with PCO2 levels 40 (±5%)
B. Mild hypercarbia arm:
Controlled ventilation with PCO2 levels 50 (±5%)
- Normalize PCO2 levels to 40 (±5%) immediately after adequate revascularization (TICI 2B)
- Baseline arterial blood gas values for correlation/correction with PCO2 level detected on ETCO2 measurements
- Mandatory extubation attempt within 60 minutes after procedure completion. Reasons for failed extubation should be documented
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Radoslav Raychev, MD
- Phone Number: 310-794-6379
- Email: rraychev@mednet.ucla.edu
Study Contact Backup
- Name: Gilda Avila
- Phone Number: 310-825-1806
- Email: GAvila@mednet.ucla.edu
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- UCLA Stroke Center
-
Contact:
- Radoslav Raychev, MD
- Phone Number: 310-794-6379
- Email: rraychev@mednet.ucla.edu
-
Contact:
- Gilda Avila
- Phone Number: 310-825-1805
- Email: GAvila@mednet.ucla.edu
-
Principal Investigator:
- Radoslav Raychev, MD
-
Sub-Investigator:
- Jeffrey Saver, MD
-
Sub-Investigator:
- Natalie Moreland, MD
-
Sub-Investigator:
- Reza Jahan, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18
- NIHSS ≥ 6 within 0-16h or NIHSS ≥ 10 within 16-24h
- Anterior circulation large vessel occlusion (ICA, M1, M2)
- ASPECTS score ≥ 6 within the first 6h, or DEFUSE trial imaging criteria within 6-16h; or DAWN trial clinical/imaging mismatch criteria within 16-24h
- Premorbid modified Rankin Scale (mRS) 0-2
- Patient deemed candidate for mechanical thrombectomy with anticipated groin puncture within 24 hours of last known well and within 90 min of ED arrival
Clinical Exclusion Criteria:
- Intubation in ED prior to anesthesiologist evaluation, or intubation for any other medical reason other than planned thrombectomy
- Rapid neurological improvement, suggestive of revascularization
- Known serious sensitivity to radiographic contrast agents.
- Current participation in another investigational drug or device treatment study.
- Renal Failure as defined by a serum creatinine > 2.0 mg/dl (or 176.8 μmol/l) or Glomerular Filtration Rate [GFR] < 30.
- Subject who requires hemodialysis or peritoneal dialysis, or who have a contraindication to an angiogram for whatever reason.
- Life expectancy of less than 90 days.
- Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT or MRI scan is normal
- Subject with a co-morbid disease or condition that would confound the neurological and functional evaluations or compromise survival or ability to complete follow up assessments.
- Subject currently uses or has a recent history of illicit drug(s) or abuses alcohol (defined as regular or daily consumption of more than 4 alcoholic drinks per day.
- Septic or cardiogenic shock with severe life-threatening hypotension
Imaging Exclusion Criteria:
- Computed tomography (CT) or Magnetic Resonance Imaging (MRI) evidence of acute intracranial hemorrhage on presentation.
- CT or MRI evidence of mass effect or intracranial tumor (except small meningioma).
- CT showing hypodensity or MRI showing hyperintensity involving greater than 1/3 of the middle cerebral artery (MCA) territory (or in other territories, >100 cc of tissue) on presentation.
- Baseline non contrast CT or DWI MRI evidence of a moderate/large core defined as extensive early ischemic changes of Alberta Stroke Program Early CT score (ASPECTS) < 6
- CT or MRI evidence that ischemia is not in anterior circulation distribution.
- Imaging evidence that suggests, in the opinion of the investigator, the subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target lesion, moderate/large infarct with poor collateral circulation, etc.).
Anesthesia exclusion criteria (relative):
- History of Malignant Hyperthermia
- History of allergic reaction/anaphylaxis to anesthetic drugs
- Inability to tolerate supine position (severe CHF)
- Chronic O2 dependence or any other known pulmonary condition that might lead to difficult extubation and prolonged mechanical ventilation including known pulmonary hypertension
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: GA with mild hypercarbia (GAH)
Controlled ventilation with target end-tidal CO2 levels 50 (±5%)
|
The desired end-tidal PCO2 levels will be achieved by endotracheal intubation and controlled ventilation
|
Active Comparator: GA with normocarbia (GAN)
Controlled ventilation with target end-tidal CO2 levels 40 (±5%)
|
The desired end-tidal PCO2 levels will be achieved by endotracheal intubation and controlled ventilation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Modified Angiographic collateral circulation assessed by blinded core lab
Time Frame: Immediately prior to revascularization
|
Modified American Society of Interventional and Therapeutic Neuroradiology (ASITN) grading scale is an ordinal 0-4 scale for angiographic collateral assessment.
It runs from 0 (no collaterals) to 4 (excellent collaterals) as follows: 0: No visible collaterals to the ischemic site; 1: Slow collaterals to the periphery of the ischemic site with persistence of some defect; 2 (-): rapid collaterals to the periphery of the ischemic site with collateral filling in <50% of the territory; 2 (+): rapid collaterals to the periphery of the ischemic site with collateral filling > 50% of the territory; 3: Collaterals with slow but complete angiographic blood flow of the ischemic bed by the venous phase; 4: Complete and rapid collateral blood flow to the vascular bed in the entire ischemic territory by retrograde perfusion.
|
Immediately prior to revascularization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
infarct growth assessed by blinded core lab
Time Frame: From the first brain imaging upon arrival to emergency department (ED) up to 72 hours after intervention
|
Infarct growth will be determined by the difference in volume (cc) between baseline and post revascularization (24-72h) infarct volume.
For patients assessed with MRI at the time of arrival to emergency department (ED), baseline infarct size will be determined on diffusion weighted imaging (DWI) or apparent diffusion coefficient (ADC) imaging.
Final infarct size measurement will performed using a T2 fluid attenuated inversion recovery sequence with additional reference to the DWI or ADC imaging at 24-72h after intervention.
For patients assessed with CT at the time of ED arrival, baseline and final (24-72h) core infarct will be determined by RAPID perfusion imaging software.
|
From the first brain imaging upon arrival to emergency department (ED) up to 72 hours after intervention
|
modified Rankin Scale assessed by a blinded investigator
Time Frame: 90 days after intervention
|
The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death: 0 - No symptoms.
|
90 days after intervention
|
safety endpoints (defined as any parenchymal hematoma (PH), subarachnoid hemorrhage (SAH), or intraventricular (IVH) associated with death, or worsening of National Institute of Health Stroke Scale score (NIHSS) by 4 or more within 24 hours)
Time Frame: from the end of thrombectoy procedure up to 24 hours after intervention
|
defined as any parenchymal hematoma (PH), subarachnoid hemorrhage (SAH), or intraventricular (IVH) associated with death, or worsening of National Institute of Health Stroke Scale score (NIHSS) by 4 or more within 24 hours
|
from the end of thrombectoy procedure up to 24 hours after intervention
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Radoslav Raychev, MD, University of California, Los Angeles
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB#18-001454
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Stroke
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Cidat, S.A. de C.V.El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco SuarezUnknownStroke | Stroke, Acute | Cerebral Stroke | Cerebrovascular Stroke | Cerebrovascular Accident, AcuteMexico
-
Centre hospitalier de l'Université de Montréal...Not yet recruitingStroke, Acute ThromboticCanada
-
University of MiamiTemporarily not availableStroke, Ischemic | Stroke, Acute | Mesenchymal Stem Cells | Acute Ischemic Stroke | Stroke/Brain AttackUnited States
-
University Hospital, MontpellierNot yet recruiting
-
Capital Medical UniversityRecruitingAcute Stroke | Ischemic Stroke, AcuteChina
-
Chonbuk National University HospitalKorean Society of Neurosonology; Ministry of SMEs and Startups, Republic of... and other collaboratorsCompleted
-
Dongzhimen Hospital, BeijingThe Second Hospital of Hebei Medical University; Peking University Third Hospital and other collaboratorsRecruitingStroke, Ischemic | Stroke, Acute | Acute Ischemic StrokeChina
-
National Taiwan University HospitalCompleted
-
University of EdinburghNHS LothianRecruiting
Clinical Trials on Tight control of end-tidal CO2 levels
-
Ankara City Hospital BilkentCompleted
-
St. Anne's University Hospital Brno, Czech RepublicRecruiting
-
University of ManitobaUnknownDelirium | Anesthesia Complication | Post-Operative ConfusionCanada
-
University Hospital, RouenCompletedHyperventilation | Hypocapnia | Hyperventilation Syndrome | Alkalosis, RespiratoryFrance
-
University Hospital, GrenobleHospices Civils de LyonRecruitingPulmonary Disease, Chronic Obstructive | Exacerbation CopdFrance
-
Changhai HospitalUnknownSedation | Monitoring | Endoscopic UltrasonographyChina
-
Neil FinerCompletedDelivery Room ResuscitationUnited States
-
Ajou University School of MedicineCompletedEffect of Pneumoperitoneum on Remifentanil Requirements in the Surgical Pleth Index-guided AnalgesiaGastric CancerKorea, Republic of
-
Ajou University School of MedicineCompletedGastric CancerKorea, Republic of
-
University of South FloridaMedtronic - MITGRecruitingRespiratory Insufficiency | Obstructive Sleep Apnea | Bariatric Surgery CandidateUnited States